Health Claims

SGLT2 inhibitors protect the kidneys by lowering pressure inside the kidney's filters and reducing harmful oxidative stress. This stops the filters from getting damaged and slows down kidney decline. Other drugs help too, but they don't reduce pressure inside the filters as effectively.

GLP-1 drugs lower blood sugar and reduce some kidney inflammation, but they don't fix the high pressure inside the kidney filters or stop the scarring process. That's why they don't protect the kidneys as well as other drugs that directly lower pressure or block scarring signals.

Finerenone works by blocking a harmful hormone signal in the heart and kidneys, which stops swelling and scarring, leading to fewer heart attacks and strokes. Other drugs lower heart risk by different methods — one makes the body get rid of extra fluid and sugar, another improves blood vessel function — but they all end up protecting the heart in similar ways.

SGLT2 inhibitors make the kidneys flush out more salt and water, which lowers blood volume and takes pressure off the heart. This prevents fluid from building up and causing heart failure flare-ups. Other drugs work on scarring or inflammation, but they don't reduce fluid overload as quickly or effectively.

SGLT2 inhibitors protect the kidneys by reducing pressure inside the kidney's filtering units, which prevents damage to the filtering cells. This effect is stronger than other drugs because it directly targets the main cause of kidney damage in diabetes — high pressure in the filters — while also reducing harmful stress in kidney cells.

GLP-1 drugs make the kidneys filter more blood under higher pressure, which hurts already damaged kidneys. This happens more in men and in people without heart failure because their kidneys are still working harder and can't handle the extra strain.

SGLT2 inhibitors make the kidneys flush out more sugar and salt, which pulls water out of the blood and reduces the amount of fluid the heart has to pump. This lowers the strain on the heart and prevents heart failure. GLP-1 agonists don't do this same fluid removal, so they don't lower heart failure risk as much.

SGLT2 inhibitors lower pressure in the kidney's main filters, which helps protect them, but they flood the lower parts of the kidney with sugar, causing those parts to break down faster. This leads to more kidney failure and earlier dialysis. GLP-1 drugs don't flood the kidney with sugar, so they preserve kidney tissue longer but don't reduce the pressure in the main filters as much. Both drugs affect the heart and lifespan the same way because they don't change how the heart or body uses energy.